Filtered By:
Condition: Hypertension
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 61 results found since Jan 2013.

Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats
Conclusion:Appearance of vascular changes in SHRSPs, before any MRI-detectable brain lesion, is coupled to active neural proliferation in the SVZ. With disease progression, only newborn astrocytes can survive, likely because of the neurotoxicity triggered by brain oedema and oxidative stress.
Source: Journal of Hypertension - July 8, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Stroke Source Type: research

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke
Conclusions: We developed an index to measure gut microbiota dysbiosis in stroke patients; this index was significantly correlated with patients' outcome and was causally related to outcome in a mouse model of stroke. Our model facilitates the potential clinical application of gut microbiota data in stroke and adds quantitative evidence linking the gut microbiota to stroke. Introduction Ischemic stroke imposes a heavy burden on society, with 24.9 million cases worldwide (1). Although intravenous thrombolysis and endovascular treatment greatly improve some patients' prognosis, the prognosis for most pa...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research

Fifty years of stroke researches in India
Tapas Kumar Banerjee, Shyamal Kumar DasAnnals of Indian Academy of Neurology 2016 19(1):1-8Currently, the stroke incidence in India is much higher than Western industrialized countries. Large vessel intracranial atherosclerosis is the commonest cause of ischemic stroke in India. The common risk factors, that is, hypertension, diabetes, smoking, and dyslipidemia are quite prevalent and inadequately controlled; mainly because of poor public awareness and inadequate infrastructure. Only a small number of ischemic stroke cases are able to have the benefit of thrombolytic therapy. Benefits from stem cell therapy in established ...
Source: Annals of Indian Academy of Neurology - February 2, 2016 Category: Neurology Authors: Tapas Kumar BanerjeeShyamal Kumar Das Source Type: research

Stroke and the Cell Therapy Saga: Towards a Safe, Swift and Efficient Utilization of cells.
Abstract The first clinical trials of cell therapy in stroke were first published in the 2000s and consisted of neural stems cells transplanted via the intracerebral pathway. Since mesenchymal stem cells showed similar capacities to differentiate into neural cells and allowed autologous cell transplantation, they were then preferentially studied, including diabetes and hypertension. More recently, bone marrow derived mononuclear cells were successfully transplanted in stroke with no need of culture processing, and simple collection by density gradient centrifugation rendering them immediately ready for use. They i...
Source: The Keio Journal of Medicine - September 29, 2017 Category: Universities & Medical Training Authors: Kubis N Tags: Keio J Med Source Type: research

Endothelial Progenitor Cells: Therapeutic Perspective for Ischemic Stroke.
Abstract Endothelial progenitor cells (EPCs), which can be cultured in vitro from mononuclear cells in peripheral blood or bone marrow, express both hematopoietic stem cell and endothelial cell markers on their surface. They are believed to participate in endothelial repair and postnatal angiogenesis due to their abilities of differentiating into endothelial cells and secreting protective cytokines and growth factors. Mounting evidence suggests that circulating EPCs are reduced and dysfunctional in various diseases including hypertension, diabetes, coronary heart disease, and ischemic stroke. Therefore, EPCs have ...
Source: CNS Neuroscience and Therapeutics - December 11, 2012 Category: Neuroscience Authors: Zhao YH, Yuan B, Chen J, Feng DH, Zhao B, Qin C, Chen YF Tags: CNS Neurosci Ther Source Type: research

Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis and hippocampal damage in brain of a spontaneously stroke model.
Abstract Stroke is the most common cause of motor disabilities and is a major cause of mortality worldwide. Adult stem cells have been shown to be effective against neuronal degeneration through mechanisms that include both the recovery of neurotransmitter activity and a decrease in apoptosis and oxidative stress. We chose the lineage Stroke Prone Spontaneously Hypertensive Rat (SHRSP) as a model for stem cells therapy. SHRSP can develop such severe hypertension that they generally suffer a stroke at approximately one year of age. The aims of this study were to evaluate whether mesenchymal stem cells (MSC) decreas...
Source: Free Radical Biology and Medicine - February 10, 2014 Category: Biology Authors: Longoni Calió M, Sousa Marinho D, Mi Ko G, Rodrigues R, Ferraz Carbonel A, Missae Oyama L, Ormanji M, Pinoti Guirao T, Luiz Calió P, Aparecida Reis L, de Jesus Simões M, Lisboa do Nascimento T, Teixeira Ferreira A, Rejane Antônio Bertoncini C Tags: Free Radic Biol Med Source Type: research

Higher numbers of circulating endothelial progenitor cells in stroke patients with intracranial arterial stenosis
Background: Bone marrow-derived endothelial stem cells participate in vascular repairs. Numbers of circulating endothelial progenitor cells (cEPCs) are associated with atherosclerosis. Fibrinogen plays a key role in atherosclerosis. Objective was to assess if cEPC counts were associated with atherosclerotic intracranial artery stenosis (IAS). Methods: Three hundred subjects (108 patients with stroke and IAS (IAS), 120 control patients with stroke without IAS (CP), and 72 healthy controls (HC)) were retrospectively analyzed. cEPCs were identified and counted by flow cytometry using CD34, CD133 and KDR. Plasma fibrinogen was...
Source: BMC Neurology - November 5, 2013 Category: Neurology Authors: Zhizhong LiuXiurong DingFang FangRuimin WangYan ChenYuetao MaGuojun ZhangXixiong Kang Source Type: research

Scientists Discover a Bone-Deep Risk for Heart Disease
Few doctors, and even fewer patients, have heard of C.H.I.P. But it is emerging as a major cause of heart attacks and stroke, as deadly as high blood pressure or cholesterol.
Source: NYT Health - January 29, 2018 Category: Consumer Health News Authors: GINA KOLATA Tags: Heart Stem Cells Leukemia Genetics and Heredity Stroke Bone Marrow Blood Arteriosclerosis and Atherosclerosis McCarroll, Steven A (1970- ) Kathiresan, Sekar Walsh, Kenneth Source Type: news

Potential Applications of Remote Limb Ischemic Conditioning for Chronic Cerebral Circulation Insufficiency
Conclusion Due to its long-term and often invisible course, CCCI has received less attention than acute cerebral ischemic stroke. However, without appropriate intervention, CCCI may lead to a variety of adverse events. Because the pathophysiological changes associated with CCCI are complex, pharmacological research in this area has been disappointing. Recent research suggests that RLIC, which is less invasive and more well-tolerated than drug treatment, can activate endogenous protective mechanisms during CCCI. In the present report, we reviewed studies related to CCCI (Table 1), as well as those related to stroke and sta...
Source: Frontiers in Neurology - May 2, 2019 Category: Neurology Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
ConclusionsIn this pilot study of 50 patients, low-dose apixaban was safe and well tolerated as thromboprophylaxis for patients with MM receiving IMiDs. No patients experienced VTE, major hemorrhage, stroke, or MI. Further randomized studies are needed to validate apixaban as a standard primary prevention anti-thrombotic strategy for patients with MM receiving IMiDs.DisclosuresMoslehi: Bristol-Myers Squibb: Consultancy, Research Funding. Jagasia: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - November 21, 2018 Category: Hematology Authors: Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R. L., Wyatt, H., Piazza, G. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Beneficial Effects of Mesenchymal Stem Cell Delivery via a Novel Cardiac Bioscaffold on Right Ventricles of Pulmonary Arterial Hypertensive Rats.
In this study, we hypothesize that local mesenchymal stem cell (MSC) delivery via a novel bioscaffold can improve RV function despite persistent PAH. To test our hypothesis, we induced PAH in adult rats with SU5416 and chronic hypoxia exposure, treated with rat MSCs delivered by intravenous injection, intramyocardial injection or epicardial placement of a bioscaffold, and then examined treatment effectiveness by in vivo pressure-volume measurement, echocardiography, histology and immunohistochemistry. Our results showed that compared to other treatment groups, only the MSC-seeded bioscaffold group resulted in RV functional...
Source: American Journal of Physiology. Heart and Circulatory Physiology - February 28, 2019 Category: Physiology Authors: Schmuck EG, Hacker TA, Schreier DA, Chesler N, Wang Z Tags: Am J Physiol Heart Circ Physiol Source Type: research

Blood Cholesterol and Outcome of Patients with Cancer under Regular Cardiological Surveillance
Curr Oncol. 2021 Feb 12;28(1):863-872. doi: 10.3390/curroncol28010085.ABSTRACTCardiovascular (CV) diseases and cancer share several similarities, including common risk factors. In the present investigation we assessed the relationship between cholesterol levels and mortality in a cardiooncological collective. In total, 551 patients receiving anticancer treatment were followed over a median of 41 (95% CI 40, 43) months and underwent regular cardiological surveillance. A total of 140 patients (25.4%) died during this period. Concomitant cardiac diseases were more common in patients who deceased (53 (37.9%) vs. 67 (16.3%), p ...
Source: Current Oncology - February 22, 2021 Category: Cancer & Oncology Authors: Anna Lena Hohneck Stephanie Rosenkaimer Ralf-Dieter Hofheinz Ibrahim Akin Martin Borggrefe Stefan Gerhards Source Type: research